All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Selinexor,Dexamethasone,Bortezomib
Therapeutic Area: Oncology Product Name: XPOVIO
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Karyopharm Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 03, 2020
Details:
XPOVIO® (selinexor, ATG-010) is a first-in-class and only-in-class oral selective inhibitor of nuclear export, developed by Antengene and Karyopharm Therapeutics Inc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2020
Details:
TYVYT® (sintilimab injection) in combination with BYVASDA® (bevacizumab biosimilar injection) demonstrated significantly improved overall survival and Independent Radiographic Review Committee progression-free survival versus sorafenib.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sugemalimab,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Product Name: CS1001
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2020
Details:
The results showed sugemalimab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer showed clinically meaningful benefit in PFS with a well-tolerated safety profile compared to chemotherapy across PD-L1 expression levels and histologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tislelizumab
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 17, 2020
Details:
The RATIONALE 303 trial is the third Phase 3 trial of tislelizumab in NSCLC that has achieved a positive outcome at interim analysis, and more importantly, marks the first global pivotal trial with a positive outcome in the tislelizumab clinical program.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): APL-1202
Therapeutic Area: Oncology Product Name: APL-1202
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The single oral drug therapy of APL-1202 has the potential to replace intravesical chemotherapy and thereby avoiding the pain and adverse reactions associated with catheterization. If proven, it should become a new choice to prevent cancer recurrence.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
The seven studies of TYVYT® (sintilimab injection) to be presented on ESMO ASIA include one Proffered Paper Oral Presentation (a Phase 3 study) and six e-posters, covering indications including lung cancer, liver cancer, gastric cancer, and esophageal cancer.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: CS1001
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: EQRx
Deal Size: $1,300.0 million Upfront Cash: $150.0 million
Deal Type: Partnership October 27, 2020
Details:
Agreement provides a pathway to bring CStone's sugemalimab and CS1003 to global patient communities by partnering with a company with an innovative business model and unique ability to commercialize these two assets competitively against established treatments.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sugemalimab
Therapeutic Area: Oncology Product Name: CS1001
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Pfizer Inc
Deal Size: $480.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration September 30, 2020
Details:
This collaboration provides financing to support CStone’s development of sugemalimab, a potential best-in-class PD-L1 antibody that is being developed for high-incidence cancer indications in China, including lung, gastric and esophageal cancers, among others.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Toripalimab,Gemcitabine
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The results of the study showed that Toripalimab in combination with Gemcitabine/Cisplatin as a first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma significantly extended the progression-free survival than Gemcitabine/Cisplatin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Sintilimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tyvyt
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Details:
The ORIENT-32 trial evaluati
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
